The chemotherapeutic strategy with a novel NF-kappa B inhibitor in bladder cancer

• Project/Area Number: 20591866
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Urology
• Research Institution: Keio University
• Principal Investigator: KIKUCHI Eiji Keio University, 医学部, 講師 (10286552)
• Co-Investigator(Kenkyū-buntansha): MIYAJIMA Akira 慶應義塾大学, 医学部, 講師 (90245572) ; OYA Mototsugu 慶應義塾大学, 医学部, 教授 (00213885)
• Project Period (FY): 2008 – 2010
• Project Status: Completed (Fiscal Year 2010)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2010: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000); Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 膀胱癌 / 転写因子 / 抗癌治療 / 抗癌剤

Research Abstract

The present study was undertaken to assess the possibility of enhancement of chemosensitivity to CPT-11 by a novel and strong NF-κB inhibitor, DHMEQ in bladder cancer. Constitutive activation of NF-κB was observed in KU19-19 cells. NF-κB was activated by the treatment with SN38. However, pretreatment with DHMEQ inhibited the activation of NF-κB induced by SN-38. The combination treatment resulted in a significantly higher level of growth inhibition compared to treatment with DHMEQ or SN-38 alone. Chemotherapy in combination with DHMEQ might be a novel therapeutic modality against bladder cancer.

Research Products

• [Journal Article] Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines. (2010)
  • Author(s): Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
  • Journal Title: Urology 75 Pages: 805-812
  • Peer Reviewed
• [Journal Article] The novel NF-κB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-thy1.1-induced glomerulonephritis in rats. (2008)
  • Author(s): Kosaka Takeo, et al
  • Journal Title: Nephron Exp Nephrol 110
  • Peer Reviewed
• [Presentation] 高悪性度膀胱癌細胞の増殖・生存における転写因子AP-1およびNF-κBの抗癌剤治療抵抗性への関与 (2010)
  • Author(s): 鈴木絵里子、菊地栄次、堀口裕、大家基嗣、梅澤一夫
  • Organizer: 第14回がん分子標的治療研究会総会・ワークショップ
  • Place of Presentation: 東京
  • Year and Date: 2010-07-07
• [Presentation] 膀胱癌に対する新規NF-κB活性阻害剤を併用した抗癌治療戦略の確立 (2010)
  • Author(s): 菊地栄次、大家基嗣
  • Organizer: 第98回日本泌尿器科学会総会・ヤングリサーチグラント受賞者記念講演
  • Place of Presentation: 盛岡
  • Year and Date: 2010-04-27
• [Presentation] 前立腺癌における新規NF-κB活性阻害剤DHMEQによる放射線感受性増強効果 (2009)
  • Author(s): 菊地栄次、堀口裕、宮嶋哲、梅澤一夫、大家基嗣
  • Organizer: 第13回がん分子標的治療研究会総会
  • Place of Presentation: 徳島
  • Year and Date: 2009-06-26
• [Presentation] 膀胱癌に対する新規NF-kappaB阻害剤を用いたCPT-11の抗癌作用増強 (2009)
  • Author(s): 菊地栄次、宮嶋哲、山崎恵一、堀口裕、中川健、中島淳、橘政昭、梅澤一夫、大家基嗣
  • Organizer: 第18回泌尿器科分子・細胞研究会
  • Place of Presentation: 鹿児島
  • Year and Date: 2009-02-13
• [Presentation] 膀胱癌における新規NF-κB活性阻害剤を用いたCPT-11の抗癌治療の増強 (2008)
  • Author(s): 菊地栄次、堀口裕、宮嶋哲、中島淳、梅澤一夫、中川健、大家基嗣
  • Organizer: 第12回がん分子標的治療研究会総会
  • Place of Presentation: 東京
  • Year and Date: 2008-06-26
• [Presentation] 膀胱癌における新規NF-κB活性阻害剤を用いたCPT-11の抗癌作用増強の検討 (2008)
  • Author(s): 菊地栄次、中島淳、堀口裕、宮嶋哲、中川健、大東貴志、山崎恵一、梅澤一夫、大家基嗣
  • Organizer: 第96回日本泌尿器科学会総会
  • Place of Presentation: 横浜
  • Year and Date: 2008-04-25